Menu

Σύνδεση Μέλους

Κλινικές Μελέτες

A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies

EudraCT / EU CT No
2024-516869-36-00
Protocol No
EXS73565-001

Trial information

Medical condition
CLL, DLBCL, MCL, MZL, WALDENSTROM, FL
Trial phase
Phase 1
Sponsor
Exscientia AI Ltd
Start date
17/06/2026
End date
Recruiting
Main objective
TEAEs, DLTs

Locations and Contact points

Greece

Site city Organisation name Department name Name Email Telephone number
Patras University Hospital of Patras Alexandros Spyridonidis +302613604169